Evaluating the use and perceptions of cannabis and vaping post-cannabis legalisation in people with cystic fibrosis and CFTR-related disorder: survey results from a large Canadian adult cystic fibrosis clinic.

BACKGROUND: This study characterised the use and perceptions of cannabis and vaping in people with cystic fibrosis (CF) and CF transmembrane conductance regulator (CFTR)-related disorder followed by a large Canadian adult CF clinic. It also aimed to assess whether cannabis legalisation in Canada affected perceived benefits and harms, and whether media attention regarding e-cigarette or vaping product use-associated lung injury (EVALI) affected perceptions of vaping.

METHODS: An electronic questionnaire was emailed to all clinic patients on 23 April 2021, and remained open until 28 October 2021.

RESULTS: 110 individuals completed the questionnaire, of whom 43% identified as a current user of cannabis. As a result of legalisation, 14% of respondents reported change in their perceptions of cannabis, primarily related to decreased stigma and increased awareness of medical indications and potential side effects. Cannabis was reported as being used medically for 85% of current users, with stress, insomnia/lack of sleep, and anxiety being the most common symptoms treated; the majority reported it to be somewhat or very effective to manage symptoms. Overall, 33% of respondents had tried vaping, but only 7% considered themselves current vapers. For 45% of respondents, the 2019 EVALI epidemic was reported to have changed perceptions of potential short-term and long-term effects associated with vaping, with increased awareness of potential harms.

CONCLUSIONS: Cannabis use was common, with a reported increase since its legalisation in this population. EVALI media attention was reported to increase awareness for potential harms associated with vaping. CF healthcare providers are well positioned to provide education and support so patients can make informed decisions about cannabis use and vaping.